• LAST PRICE
    5.5700
  • TODAY'S CHANGE (%)
    Trending Down-0.6800 (-10.8800%)
  • Bid / Lots
    5.5500/ 3
  • Ask / Lots
    5.6000/ 5
  • Open / Previous Close
    6.0100 / 6.2500
  • Day Range
    Low 5.4500
    High 6.0800
  • 52 Week Range
    Low 5.2500
    High 51.9500
  • Volume
    226,453
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 6.25
TimeVolumeSYRS
09:32 ET38916.05
09:34 ET27315.95
09:36 ET31085.9509
09:38 ET8496.0393
09:39 ET5005.9501
09:45 ET4026.01
09:50 ET2006
09:52 ET88445.9514
09:54 ET5315.93
09:56 ET2005.91
09:57 ET1005.9
10:01 ET44975.9
10:03 ET6135.88
10:06 ET34715.7988
10:08 ET18575.7
10:10 ET21235.68
10:12 ET8585.69
10:14 ET13215.79
10:15 ET32195.7931
10:17 ET2455.7607
10:19 ET2405.775
10:21 ET11035.76
10:24 ET44315.75
10:26 ET21005.75
10:28 ET167105.74
10:30 ET27595.74
10:32 ET94895.68
10:33 ET45665.6888
10:35 ET22905.6795
10:37 ET6085.6712
10:39 ET40615.67
10:42 ET21455.68
10:44 ET4195.665
10:46 ET2325.6888
10:48 ET2005.6648
10:50 ET1105.6512
10:53 ET6585.673
10:55 ET14005.68
10:57 ET3205.67
11:00 ET1005.665
11:04 ET2005.67
11:06 ET1005.67
11:08 ET6305.67
11:09 ET5105.68
11:15 ET2005.67
11:18 ET7005.67
11:20 ET4745.6612
11:22 ET2285.6756
11:24 ET7005.6801
11:26 ET4015.705
11:27 ET10005.7
11:29 ET3465.705
11:31 ET2005.72
11:33 ET2895.7199
11:38 ET1975.71
11:40 ET3455.7014
11:45 ET6505.71
11:47 ET7145.69
11:49 ET4505.6848
11:51 ET1605.67
12:02 ET1005.68
12:05 ET11305.66
12:12 ET1005.64
12:14 ET1315.6112
12:16 ET7845.6088
12:20 ET1005.61
12:23 ET1135.605
12:25 ET6945.6012
12:32 ET1005.6
12:34 ET4335.55
12:38 ET4175.52
12:39 ET10005.51
12:41 ET2505.51
12:43 ET2005.505
12:48 ET4645.5
12:50 ET1575.5099
12:56 ET2005.505
12:57 ET80255.4784
12:59 ET1005.465
01:01 ET12505.475
01:03 ET1435.45
01:06 ET10905.4548
01:08 ET24895.47
01:10 ET6145.46
01:14 ET16675.47
01:15 ET2005.46
01:17 ET6765.4708
01:21 ET2005.4512
01:24 ET1295.4759
01:35 ET2545.47
01:51 ET1105.47
01:53 ET18345.49
01:57 ET3005.5
02:00 ET5005.4955
02:02 ET1005.48
02:04 ET18025.4985
02:15 ET6005.4895
02:18 ET4395.4823
02:20 ET11645.48
02:24 ET2425.4915
02:31 ET68235.51
02:44 ET1535.49
02:51 ET43725.5001
02:54 ET2705.5107
03:02 ET1005.505
03:03 ET5205.51
03:05 ET1005.51
03:07 ET6465.5
03:09 ET9505.52
03:12 ET8005.54
03:14 ET3585.51
03:16 ET1005.5189
03:18 ET1175.5176
03:21 ET1195.5008
03:23 ET4005.5199
03:25 ET6005.5168
03:27 ET3005.5001
03:30 ET14005.52
03:32 ET5005.55
03:34 ET6805.5485
03:36 ET46085.53
03:38 ET6005.53
03:39 ET4005.54
03:41 ET9515.51
03:43 ET13285.5499
03:45 ET3865.55
03:48 ET8405.56
03:50 ET20305.58
03:52 ET5005.57
03:54 ET10795.5591
03:56 ET8905.57
03:57 ET19655.6
03:59 ET9635.57
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSYRS
Syros Pharmaceuticals Inc
35.1M
-0.3x
---
United StatesHARP
Harpoon Therapeutics Inc
31.2M
-0.4x
---
United StatesCDAK
Codiak BioSciences, Inc.
30.3M
-0.9x
---
United StatesANGN
Angion Biomedica Corp
30.1M
-1.2x
---
United StatesCASI
CASI Pharmaceuticals Inc
35.6M
-1.1x
---
United StatesMDWD
Mediwound Ltd
56.6M
-2.6x
---
As of 2022-09-25

Company Information

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on redefending the power of small molecules to control the expression of genes. The Company is engaged in developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases, and building a clinical-stage pipeline of gene control medicine. The Company's lead product candidates include Tamibarotene, SY-2101 and SY-5609. Its Tamibarotene, is a selective retinoic acid receptor alpha (RARĪ±), agonist RARA-positive patients with higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML). Its SY-2101, is an oral form of arsenic trioxide (ATO) being developed for the treatment of acute promyelocytic leukemia (APL). Its SY-5609, is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) which is being development for patients with select solid tumors and blood cancers.

Contact Information

Headquarters
35 Cambridge Park DriveCAMBRIDGE, MA, United States 02140
Phone
617-744-1340
Fax
617-744-1377

Executives

Independent Chairman of the Board
Peter Wirth
President, Chief Executive Officer, Director
Nancy Simonian
Chief Financial Officer
Jason Haas
Chief Scientific Officer
Eric Olson
Chief Commercial Officer
Conley Chee

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$35.1M
Revenue (TTM)
$25.2M
Shares Outstanding
6.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.70
EPS
$-17.31
Book Value
$13.74
P/E Ratio
-0.3x
Price/Sales (TTM)
1.4
Price/Cash Flow (TTM)
---
Operating Margin
-446.70%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.